<DOC>
	<DOCNO>NCT00583947</DOCNO>
	<brief_summary>To determine safety tolerability Arformoterol Tartrate child asthma</brief_summary>
	<brief_title>A Safety Tolerability Study Arformoterol Tartrate Inhalation Solution Pediatric Subjects</brief_title>
	<detailed_description>A randomized , double-blind two-way crossover study three cumulative dos arformoterol ( 7.5 ug per nebulization ) levalbuterol ( 0.63 mg per nebulization ) give one hour period , follow single open-label treatment day three cumulative dos arformoterol 15 ug subject 2-11 year age asthma . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Male Female Between Age 2 11 , inclusive , time consent Weight equal great 15 Kg History physiciandiagnosed asthma least 2 year duration child age 6 old , least 1 year duration child 5 young . Female subject pregnant lactating . Subject history hospitalization asthma within one year , schedule inpatient hospitalization , include elective surgery course trial . Subject history lifethreatening asthma define history asthma episodes require intubation , associate hypercapnia , respiratory arrest , hypoxic seizure . Subject history cancer . Subject hyperthyroidism , diabetes , hypertension , cardiac disease seizure disorder . Subject history cigarette smoking use tobacco product .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
</DOC>